shares of eli lilly and incyte downgraded today, cut to neutral at piper jaffrey.d their new daily pill to treat rheumatoid arthritis citing more clinical data needed to determine appropriate doses. lilly reaffirming full year guidance, though, and potential impact of the decision on its bottom line. look at that. it's eli lilly down 4%. giant company, of course rs and incyte down more than 10% in the trade. >> might have thought the hit was bigger. this happened friday when markets were closed as others mentioned. the drug was proved in europe, but not here, though. >>> a rally. we had rallies in the last few weeks, couple days, but they faded into the afternoon. that's not happening today. we're at the highs of the session right now. the industrial average up 158 points. increase of more than three quarters a percent. >> it's the weather. >> i don't know. expectation for earnings. as we established, when you get treasury secretary saying the timetable for tax reform is now being pushed back again -- >> taking that in stride. >> any other day, that would have sent